Document is current

Article History

Received: 8 February 2024

Revised: 19 June 2024

Accepted: 20 June 2024

First Online: 26 July 2024

Competing interests

: CA is currently holding a grant from the Christian Doppler Research Association (CD Laboratory for Inner Ear Research) and is receiving funding from MED-EL Corporation, Innsbruck, Austria. MN, EY, AJG and MG were financed by this funding while conducting the studies. LDL receives research funding from Decibel Therapeutics/Regeneron Pharmaceuticals and Amgen and has worked as an independent consultant for Gerson Lehrman Group and Conclave Capital. SBr and PM are employed by MED-EL as Senior Research Specialists and were involved in conceptualization of the study design. RS and HR are CEO and CSO of Audiocure Pharma GmbH, developing the compound AC102. Both had no involvement during conduction of the study or during analysis of the results. MK and SB are employees of Audiocure Pharma GmbH. The remaining authors declare no conflict of interest. The funding sources did not influence the study design, the interpretation of the data or the decision to publish this article.

: Animal care, treatments and procedures were performed according to the guidelines of the Austrian Federal Ministry for Science, Research and Economy. All animal experiments were approved by the local animal welfare committee (66.009/0094-V/3b/2019).